Is GEHC a good stock to buy?
GE HealthCare Technologies Inc. · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 23
- P/E vs sector-32.7%
- News
- MAs4 of 4
- MACD0.22
- Sector▲ +15.9%
- Earnings in82d
- P/E21.7x
- RSI68
- Support-0.2%
- Resistance+4.0%
- Off 52w high-7.5%
- Volume0.6x
- Bollingerupper half
- FCF yield+3.2%
- P/E vs own+8.6%
- PT$83.06 +0.1%
- Trendsideways
- 52w range$59–$90
- ATR+2.8%
- Off ATH-12.4%
- InsidersNone in 90d
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is GE HealthCare a good stock to buy?
GE HealthCare is strong on 2 of the 3 questions about the business; weak on demand. The price is about usual: 21.7 times its earnings, near its 3-year median of 20.2 (Nov 13, 2026). pretickt does not say whether to buy or sell.
GEHC earnings vs estimates
7 of 8quarters above the analysts' estimateGE HealthCare beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 28, 2026.
GEHC insider buying
+$6.42Mbought, net, by its executives in 12 monthsGE HealthCare's executives and directors bought a net $6.42M of shares in the 12 months to Nov 13, 2026; none sold.
GEHC number of employees
+2%more people in a yearGE HealthCare had 54,000 employees at the end of fiscal 2025, 2% more than a year before.
GEHC financial health Altman Z-score
2.0Altman Z-score, safe above 3GE HealthCare's Altman Z-score is 2.0 (Nov 13, 2026), between 1.8 and 3, the grey zone.
GEHC biggest customers
under 10%of sales from any one customerNo customer made 10% of GE HealthCare's sales in fiscal 2025.
GEHC price vs profit P/E ratio
21.7×a year's earningsGE HealthCare's P/E ratio is 21.7 (Nov 13, 2026), near its 3-year median of 20.2.
GEHC price vs competitors
pretickt analysis21.7×a year's earnings, against its competitorsInvestors pay 21.7 times GE HealthCare's earnings (Nov 13, 2026), more than for Boston Scientific (18.8), less than for Edwards Lifesciences (60.5), Dexcom (32.7) and Zimmer Biomet (26.1).
GEHC analysts' target price target
0%to their average targetAnalysts' average price target for GE HealthCare is $83.06, 0% above the Nov 13, 2026 close of $83.02.
GEHC growth priced in fair value
pretickt analysis+13%a year, for ten years, to be worth the priceAt $83.02 a share, GE HealthCare's free cash flow must grow about 13% a year for ten years to be worth the price (Nov 13, 2026).
What is GE HealthCare's P/E ratio?
GE HealthCare's P/E ratio is 21.7 (Nov 13, 2026), near its 3-year median of 20.2. Investors pay 21.7 times GE HealthCare's earnings (Nov 13, 2026), more than for Boston Scientific (18.8), less than for Edwards Lifesciences (60.5), Dexcom (32.7) and Zimmer Biomet (26.1).
Who are GE HealthCare's biggest competitors?
pretickt compares GE HealthCare with Dexcom, Edwards Lifesciences, Boston Scientific and Zimmer Biomet. GE HealthCare's sales grew 2% in the 12 months to Sep 30, 2026, slower than Edwards Lifesciences (+13%), Dexcom (+13%), Boston Scientific (+9%) and Zimmer Biomet (+7%).
Are insiders buying GE HealthCare stock?
GE HealthCare's executives and directors bought a net $6.42M of shares in the 12 months to Nov 13, 2026; none sold.
How many employees does GE HealthCare have?
GE HealthCare had 54,000 employees at the end of fiscal 2025, 2% more than a year before.
Who are GE HealthCare's biggest customers?
No customer made 10% of GE HealthCare's sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.